Figure 4
From: MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1
MiR-494 directly targets PAK1 in breast cancer. (a) Schematic of predicted miR-494 binding sites in human PAK1-3′UTR. (b) Schematic diagram illustrating the mutant site of PAK1-3′UTR. (c) The psiCHECK-2 reported plasmids are transiently transfected into HEK293T cells. Luciferase activities are measured after 24 h. (d) Western blot assays of PAK1 expression in breast cancer cell lines MDA-231-LUC and BT-549 transfected with miR-NC or miR-494, β-actin serves as loading control. (e) ISH assays of the expression of PAK1 and miR-494 in breast cancer patient samples. (f) The static column of miR-494 (Log10 (mean IOD)) and PAK1 (Log10 (mean IOD)) expression in patient samples (P and T mean adjacent paratumor and paired tumor tissues, respectively). (g) The correlation of miR-494 (Log10) and PAK1 (Log10) in clinical breast cancer samples (tissue microarray). Data are presented as mean±S.D. The symbols *, ** and *** represent great significant difference (P<0.05, P<0.01 and P<0.001) by two-tailed Student’s t-test
